PackGene and CMRI Join Forces for Innovative AAV Solutions
In an exciting development for gene therapy research, PackGene Biotech has entered into a strategic licensing agreement with the Children's Medical Research Institute (CMRI). This partnership aims to deliver advanced AAV Capsid Screening Kits that will significantly enhance the capabilities of researchers in the field of gene therapy.
Unveiling the High-Throughput AAV Capsid Screening Kits
These cutting-edge screening kits are designed to enable rapid and efficient evaluation of AAV capsids in in vitro, ex vivo, and in vivo setups. With a focus on facilitating the identification of effective AAV capsids for tissue-specific gene delivery, researchers can now streamline their development processes and optimize therapeutic outcomes.
Key Features and Benefits of the AAV Screening Kits
The AAV Capsid Screening Kits incorporate customizable variants that have been developed by CMRI and produced by PackGene. These kits not only support high-throughput screening but also provide access to proprietary novel capsids. Such innovations promise enhanced properties, including greater tissue specificity, reduced off-target effects, and improved overall productivity.
Insights from Leading Researchers
Leading the project is Professor Leszek Lisowski, Head of the Translational Vectorology Research Unit at CMRI. Professor Lisowski highlights the pioneering efforts of CMRI in creating barcoded AAV capsid kits. These kits allow large-scale evaluation of AAVs, measuring their effectiveness in terms of cell entry and transgene expression. This advanced methodology aims to lower costs and decrease reliance on extensive preclinical trials. “We are thrilled to collaborate with PackGene. Our mission is to provide researchers with superior tools to expedite the discovery of functional AAV variants,” stated Prof. Lisowski.
PackGene’s Commitment to Affordable Gene Therapy
Dr. Xin Swanson, Chief Strategy Officer at PackGene, expressed that the partnership aligns perfectly with PackGene’s mission to make gene therapy more accessible. By combining CMRI's innovative approaches with PackGene's established expertise in AAV vector design and scalable production, this collaboration ensures that customers can navigate development with greater confidence. This revolutionary advancement in high-throughput screening holds the potential to accelerate the creation of state-of-the-art gene therapies, bringing invaluable treatments to patients more swiftly.
About PackGene Biotech
PackGene Biotech Inc. stands out as a leading contract research organization (CRO) and contract development and manufacturing organization (CDMO), with a focus on AAV, mRNA, plasmid DNA, and lentiviral vector technologies. The company is headquartered in Houston, Texas, and offers comprehensive services that span from vector design to GMP manufacturing. With the proprietary ?-alpha 293 AAV production platform, PackGene sets the industry standard by achieving yields up to 1e+17 vg per batch, thus supporting effective production for both preclinical and clinical applications.
About Children's Medical Research Institute (CMRI)
CMRI, located in Westmead, Australia, is globally recognized for its commitment to understanding and curing serious childhood diseases. The institute features the Vector and Genome Engineering Facility (VGEF), Australia's premier publicly-accessible AAV engineering facility. Through innovations like the barcoded AAV testing platform, CMRI is at the forefront of redefining how vector performance is assessed and optimized.
Frequently Asked Questions
What is the purpose of the AAV Capsid Screening Kits?
The AAV Capsid Screening Kits are designed to facilitate rapid evaluation of AAV capsids for gene therapy applications, ensuring effective tissue-specific delivery.
How does this partnership benefit researchers?
Researchers gain access to customizable kits and proprietary capsids that improve tissue specificity and reduce preprocessing requirements, enhancing their research efficiency.
Who are the key figures in this partnership?
Professor Leszek Lisowski from CMRI and Dr. Xin Swanson from PackGene are the leading experts steering this innovative initiative.
What sets PackGene apart in the AAV technology space?
PackGene is known for its expertise in AAV vector design and high-yield production capabilities, making significant strides in gene therapy accessibility.
What advancements can we expect from using these kits?
The kits aim to enhance the speed and efficacy of AAV capsid evaluation, driving forward the development of next-generation gene therapies.
